The mammalian CTLH complex is an E3 ubiquitin ligase that targets its subunit muskelin for degradation

Matthew E. R. Maitland1,2,3, Gabriel O'nea1,2, Christopher A. Chiasson1,2, Xu Wang1, Jun Ma2,3, Sarah E. Moor1,2, Kathryn R. Barber2, Gilles A. Lajoie2,3, Gary S. Shaw1 & Caroline Schild-Poulter1,2

The multi-subunit C-terminal to LisH (CTLH) complex is the mammalian homologue of the yeast Gid E3 ubiquitin ligase complex. In this study, we investigated the human CTLH complex and characterized its E3 ligase activity. We confirm that the complex immunoprecipitated from human cells comprises RanBPM, ARMC8α/β, muskelin, WDR26, GID4 and the RING domain proteins RMND5A and MAEA. We find that loss of expression of individual subunits compromises the stability of other complex members and that MAEA and RMND5A protein levels are interdependent. Using in vitro ubiquitination assays, we demonstrate that the CTLH complex has E3 ligase activity which is dependent on RMND5A and MAEA. We report that the complex can pair with UBE2D1, UBE2D2 and UBE2D3 E2 enzymes and that recombinant RMND5A mediates K48 and K63 poly-ubiquitin chains. Finally, we show a proteasome-dependent increase in the protein levels of CTLH complex member muskelin in RMND5A KO cells. Furthermore, muskelin ubiquitination is dependent on RMND5A, suggesting that it may be a target of the complex. Overall, we further the characterization of the CTLH complex as an E3 ubiquitin ligase complex in human cells and reveal a potential autoregulation mechanism.

Ubiquitination, the addition of the 76 amino acid protein ubiquitin to lysine residues on target proteins, modifies protein function or turnover and regulates a wide spectrum of biological processes in development and disease. The three-step mechanism is initiated by ATP-dependent activation of ubiquitin by E1 enzymes, conjugation to E2 enzymes and covalent attachment to a substrate recruited by an E3 ligase. Subsequent elongation of ubiquitin molecules forms poly-ubiquitin chains, linked through one of its seven lysine residues or N-terminal methionine. The type of linkage dictates the fate and function of the ubiquitinated protein. For example, poly-ubiquitinated chains linked through lysine 11 (K11) or 48 (K48) are known to target proteins for proteasomal degradation, while lysine 63 (K63) linked chains can trigger lysosomal degradation, endocytosis, regulate protein trafficking, or alter protein interactions.

E3 ligases with Really Interesting New Gene (RING) finger domains mediate direct transfer of ubiquitin to the substrate from the E22,3. The RING domains coordinate two Zn2+ ions in a cross-braced arrangement critical for its structure, or without Zn2+ coordination in the case of the U-box family of E3 ligases in which case polar and charged residues substitute for the Zn2+ ions. Approximately 600 RING finger E3 ligases exist in the human genome, underlying their importance in cell signaling regulation and the diversity of their substrates. RING E3 ligases exist as monomers, homodimers, heterodimers, or in multi-subunit complexes, such as the Cullin RING ligases, which contain subunits that function either as a scaffold, adaptor, or substrate recognition element, in addition to the RING subunit.

The glucose-induced degradation deficient (Gid) complex is a multi-subunit E3 ligase in Saccharomyces cerevisiae. Upon replenishment of glucose to starved yeast cells, the Gid complex ubiquitinates gluconeogenic enzymes.
such as fructose-1,6-bisphosphatase (Fbp1), phosphoenolpyruvate carboxykinase (Pck1) and malate dehydrogenase (Mdh2), leading to their proteasomal degradation\(^6\). These substrates are targeted by the complex via recognition of their N-terminal proline residues by Gid4 in the complex by a process termed the Pro/N-end rule pathway\(^6\). Gid4 is rapidly synthesized after glucose addition and associates with the Gid complex, thus triggering the ubiquitination of the gluconeogenic enzymes and allowing the cells to switch from gluconeogenesis to glycolysis\(^2\).

In the Gid complex, Gid2 and Gid9 both contain conserved RING finger domains and form a heterodimer\(^7\). Ubiquitin ligase activity has been demonstrated \textit{in vitro} for yeast Gid2\(^7\) and its \textit{Xenopus laevis} orthologue\(^3\). For Gid9, mutation of a cysteine residue in its RING domain abrogates ubiquitination and degradation of the gluconeogenic targets of the Gid complex, although activity of Gid9 in \textit{in vitro} assays could not be demonstrated\(^2\).

The C-terminal to LisH (CTLH) complex is the mammalian homologue of the Gid complex\(^16\). It was originally identified by analysis of Ran binding protein M (RanBPM, also known as RanBP9) associated proteins in a high molecular weight fraction of HEK293 extracts, consisting of muskelin, Two Hybrid-Associated Protein 1 With RanBP (TWa1, also known as GID8), Armadillo Repeat Containing 8 (ARMC8) isoforms \(\alpha\) and \(\beta\) and two subunits containing RING domains, Macrophage Erythroblast Attacher (MAEA, also known as EMP; homologue of Gid9) and Required For Meiotic Nuclear Division 5 Homolog A (RMND5A; homologue of Gid2)\(^10\). The CTLH complex was named following the observation that five of the complex members contain LIS1-homology motif (LisH) and CTLH domains\(^10,13\).

The most well-studied complex member is RanBPM, a 90 kDa ubiquitously expressed, nucleocyttoplasmic and evolutionarily conserved protein implicated in a variety of cellular functions\(^15\). RanBPM is a regulator of multiple signaling pathways, including the ERK pathway, Transforming growth factor-\(\beta\) (TGF-\(\beta\)), histone deacetylase 6 (HDAC6) activity and the Ataxia Telangiectasia Mutated (ATM)-dependent DNA damage response\(^15-17\). Other CTLH subunits, such as muskelin, have been implicated in intracellular protein trafficking, microtubule dynamics and cell adhesion, whereas MAEA has been found to regulate erythroblast and macrophage maturation\(^18-21\). Few studies so far have evaluated the biological function of the complex in mammalian cells\(^15,22,23\). While most subunits of the complex are conserved within eukaryotic lineages and the RING domains in MAEA and RMND5A share high levels of conservation with their yeast counterparts\(^10\), the composition, activity and function of the complex remain to be characterized.

In this study, we further characterize the CTLH complex and investigate its E3 ubiquitin ligase activity in human cells. We find that WD repeat-containing protein 26 (WDR26) and GID4 are components of the CTLH complex and that complex members are differentially distributed within nuclear and cytoplasmic compartments. Through analysis of knockout cell lines of CTLH subunits, we determine that the stability of several complex members is interdependent and that, in particular, RanBPM and TWa1 are critical for complex stability. We show that the complex has E3 ligase activity and that this is dependent on both RMND5A and MAEA. Furthermore, we characterize the E2 pairings of the complex and ubiquitin linkage. Finally, we determine that the stability and ubiquitination of CTLH complex member muskelin is regulated by the complex, suggesting that this may be part of an autoregulatory mechanism.

**Results**

**WDR26 and GID4 are CTLH complex members.** The initial characterization of the CTLH complex determined that it was composed of 6 subunits, RanBPM, TWa1, muskelin, ARMCh and the RING domain proteins RMND5A and MAEA (Fig. 1a)\(^13,14\). We confirmed the composition of the complex by immunoprecipitation of RanBPM in HEK293 cells and found that CTLH complex members remain associated with RanBPM even under stringent conditions (Fig. 1b, Supplementary Fig. 1). WD Repeat Domain 26 (WDR26) and human GID4 (also known as c17orf39), the homologues of the yeast Gid complex members Gid7 and Gid4, respectively, were not detected in the initial identification of the complex\(^13\). In contrast, we found that endogenous WDR26 associates with RanBPM (Fig. 1b) and that CTLH complex members co-immunoprecipitate with exogenously expressed WDR26 and GID4 (Fig. 1c,d), consistent with recent interactome studies that revealed the human proteins do associate with the complex\(^24,25\). Taken together, this works shows that WDR26 and GID4 are CTLH complex subunits.

To compare the subcellular localizations of all complex members, we transfected HA or FLAG tagged constructs of RanBPM, TWa1, ARMCh, RMND5A, MAEA, muskelin, WDR26 and GID4 in HeLa cells (Fig. 2a). Consistent with a previous report\(^26\), RanBPM, TWa1, ARMCh and RMND5A showed nucleocyttoplasmic distribution, with a nuclear predominance, while muskelin appeared mostly cyttoplasmic and MAEA nearly exclusively nuclear (Fig. 2b). Interestingly, GID4 displayed a near exclusive nuclear staining and WDR26 was primarily cytoplasmic (Fig. 2a,b). The differing subcellular localization of CTLH complex members suggests the possibility that several complexes of varying composition may co-exist in the nucleus and cytoplasm.

**Interdependence of CTLH complex subunit stability.** The RanBPM and TWa1 yeast homologues Gid1 and Gid8, respectively, form the core of the Gid complex with MAEA and RMND5A homologues (Gid9 and Gid2), which form a heterodimer (Fig. 1a). The remaining 3 subunits, Gid7, Gid5 and Gid4, the yeast homologues of WDR26, ARMCh and GID4/C17orf39, respectively, were predicted to be located on the periphery of the complex\(^15,28\). If this topology is similar in the CTLH complex, RanBPM and TWa1 would be expected to be critical for complex stability. To determine how CTLH complex subunit expression influences each other, we assessed the levels of CTLH individual subunits in stable shRNA knockdown or CRISPR knockout (KO) cell lines for six of the complex members. We found that depletion of RanBPM or TWa1 strongly affected each other's protein levels as well as that of MAEA and RMND5A (Fig. 3a,b). TWa1 knockout also had a surprising inhibitory effect on the stability of ARMCh, while ARMCh\(\alpha\) was not significantly changed (Fig. 3b). Interestingly, the RING dimer
partners MAEA and RMND5A appeared to require each other for stability as knockout of each one individually significantly reduced the protein levels of the other (Fig. 3c,d). No other prominent change was seen in RMND5A and MAEA KO cell lines, except that both showed a significantly higher amount of muskelin (Fig. 3c,d). This was also observed in RanBPM shRNA cells, albeit to a lesser extent potentially owing to the partial downregulation of RanBPM in these cells (Fig. 3a). Knockout of ARMC8 resulted in downregulation of MAEA, RMND5A and TW A1 (Fig. 3e), suggesting that TW A1, MAEA/RMND5A and ARMC8 influence each other’s stability. Finally, the knockout of muskelin only had subtle effects, if any, on protein levels of other complex members (Fig. 3f).

To determine whether these changes occurred at the mRNA level, we performed RT-qPCR analyses to evaluate whether the KO of individual subunits had an effect on the transcriptional regulation of other CTLH complex members. We did not detect any change in mRNA expression for most of the subunits tested, except for a small reduction of muskelin and MAEA mRNA in RMND5A KO cells, and a slight decrease for RMND5A mRNA in ARMC8 KO cells (Supplementary Fig. 2). In all cases, these changes were much smaller than the effects observed at the protein level (or even opposite in the case of muskelin) and therefore unlikely to account for the full extent of the effect observed at the protein level. Altogether, this substantiates that the knockout of individual complex members affects the stability of other complex members mostly at the protein level.

Finally, we used a combination of transient siRNA knockdown and subunit re-expression in knockout cell lines to confirm that these changes were not due to off-targets effects. We confirmed that siRNA downregulation of TW A1, muskelin and RMND5A recapitulated the changes observed in TW A1, muskelin and RMND5A CRISPR KO cells (Supplementary Fig. 3). Similarly, RanBPM KO cells showed similar changes in CTLH subunits as the RanBPM shRNA cells and transient re-introduction of Flag-MAEA in MAEA KO cells restored the expression of RanBPM, ARMC8 and muskelin close to the levels observed in WT cells (Supplementary Fig. 3).

**Characterization of the CTLH complex E3 ligase activity.** To determine whether the mammalian CTLH complex has E3 ligase activity, we conducted *in vitro* ubiquitination assays with the CTLH complex.
immunoprecipitated from HEK293 cells via a RanBPM antibody (as in Fig. 1b). For these assays, we supplemented the reactions with the E2 enzyme UBE2D2 (UbcH5b) because it paired with the yeast RMND5A counterpart (Gid2) in *in vitro* assays and was also identified as an interacting partner for human RMND5B, a paralog of RMND5A, in a large protein interaction screen. Ubiquitination products were observed when the CTLH complex was immunoprecipitated from wild-type HEK293 cells, but not in RMND5A knockout HEK293 cells (Fig. 4a). As the complex is intact in the RMND5A KO cells (save for RMND5A, Supplementary Fig. 4), this result demonstrates that RanBPM immunocomplexes have E3 ligase activity and that it is dependent on RMND5A, a RING domain CTLH complex subunit. To understand the contributions of MAEA to the E3 ligase activity of the CTLH complex, we conducted *in vitro* ubiquitination assays with the RanBPM immunocomplexes in control and MAEA knockout HEK293 cells. As anticipated, limited E3 ligase activity was observed in the MAEA KO cells (Fig. 4b); however, consistent with the yeast Gid complex topology, co-IP of RMND5A was not detected in MAEA KO cells. Therefore, the loss of activity could be attributed to the absence of RMND5A.

To further characterize the E3 ligase activity of the RING domain subunits RMND5A and MAEA, we conducted *in vitro* ubiquitination assays with bacterially expressed proteins. Initial experiments using purified GST-RMND5A and SUMO-MAEA failed to show any detectable activity (data not shown), possibly due to poor folding or insolubility of these enzymes. Therefore, we omitted the purification step and conducted E3 ligase assays using crude bacterial extracts as previously done to test the activity of Gid2 and Gid9. In these conditions, human GST-RMND5A exhibited weak, but observable substrate and self-ubiquitination activity (Fig. 5a). Previous studies reported that the bacterially expressed yeast Gid9, the homologue of MAEA, had no detectable E3 ligase activity *in vitro*. However, *in vivo*, a cysteine mutation in the MAEA RING domain abolished Gid complex ubiquitination of FBPase, suggesting that the RING domain of Gid9 is required for the Gid complex activity. Surprisingly, a SUMO tagged recombinant version of human MAEA expressed in *Escherichia coli* exhibited some E3 ubiquitin ligase activity (Fig. 5b), albeit weaker than that of RMND5A. Thus, both recombinant RMND5A and MAEA display E3 ligase activity *in vitro*.

**Characterization of E2 pairings and lysine linkage.** As E3 ligase ubiquitination activity is dependent on a specific E2 enzyme, we sought to determine which E2 enzymes function optimally with the CTLH complex. In a panel of 11 E2 enzymes, the GST-RMND5A fusion protein exhibited E3 ligase activity only when UBE2D1 (UbcH5a) or UBE2D2 (UbcH5b) are present in the reaction (Fig. 6a, Supplementary Fig. 5), while RanBPM immunocomplexes were able to function with UBE2D1, UBE2D2 and UBE2D3 (Fig. 6b). Interestingly, the complex or GST-RMND5A did not exhibit activity when paired with UBE2H (Ubc8), the human homologue of yeast Gid3 (also known as ubc8), which is the E2 required for the glucose-induced ubiquitination of FBPase. Similarly, no activity was detected with CDC34 (Fig. 6b), which has a C-terminal extension of acidic residues similar to that of Gid3 that is critical for its activity.

To assess which type of chain linkage is being mediated by RMND5A when paired with UBE2D2, we trypsin/LysC digested the GST-RMND5A ubiquitination assay reactions and analyzed the modified ubiquitin peptides using mass spectrometry. In the GST-RMND5A assays with UBE2D2, approximately 80% of modified ubiquitin...
was ubiquitinated on K48, while the remaining 20% was K63 (Fig. 6c, Supplementary Fig. 6). No other lysine linkages were detected. This suggests that RMND5A can mediate both K48 and K63 ubiquitin chains, with a preference for K48.

Muskelin is a target of the CTLH complex. Muskelin is the only member of the CTLH complex that does not have a yeast homologue in the Gid complex and therefore stands out as a unique difference between the two complexes. Interestingly, muskelin protein levels were significantly increased in both RMND5A and MAEA KO cells compared to control HeLa cells and this was reversed by the reintroduction of RMND5A and MAEA into their respective knockout cells by transient transfection (Figs 3c,d and 7a and Supplementary Fig. 3). Treatment with the proteasome inhibitor MG132 resulted in increased muskelin levels in control cells relative to

Figure 3. RanBPM and TWA1 are essential for complex stability. Whole cell extracts prepared from control shRNA and RanBPM shRNA HEK293 cells (a), or from control (labelled as C), TWA1, RMND5A, MAEA, ARMC8 and muskelin HEK293 CRISPR knockout cells (b–f) were analyzed by Western blot with antibodies to CTLH complex members, as indicated. Vinculin was used as a loading control. Quantifications are shown below each blot and protein levels are shown relative to control cells set to 1 and normalized to Vinculin levels. Data represent averages from three separate experiments, with error bars indicating SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
DMSO control treatment, but not in RMND5A KO HeLa cells (Fig. 7b), suggesting that the increase in muskelin in RMND5A KO cells is proteasome dependent. To confirm that muskelin protein stability was dependent on the CTLH complex, we performed cycloheximide (CHX) treatments to compare muskelin degradation of WT and RMND5A KO cells. Muskelin had a half-life of about 24 hours in WT cells, whereas no significant degradation was detected in RMND5A KO cells, even 36 hours following addition of CHX, suggesting that muskelin degradation is dependent on the CTLH complex activity (Fig. 7c). This led us to suspect that muskelin could be a ubiquitination target of the complex leading to proteasomal degradation.

To evaluate if ubiquitination of muskelin is regulated by the CTLH complex, we co-transfected HA-ubiquitin and a construct encoding FLAG-muskelin in control or RMND5A KO HEK293 cells, followed by treatment with MG132. FLAG pulldown of transfected muskelin and hybridization with an HA antibody showed a poly-ubiquitination pattern in control cells which was reduced to background levels in RMND5A KO cells (Fig. 7d). Furthermore, endogenous ubiquitinated muskelin co-immunoprecipitated with transfected HA-ubiquitin in control cells but not in RMND5A KO cells (Fig. 7e). Together, this suggests that the CTLH complex is required for muskelin ubiquitination in vivo. Overall, the data suggests that the CTLH complex regulates ubiquitination and protein levels of one of its own subunits, muskelin.

Discussion

In this study, we have characterized the composition and stability of the CTLH complex and demonstrated, using in vitro assays, that the complex has E3 ligase activity. We confirmed that human GID4 and WDR26 associate with the complex and that RanBPM, TWA1, MAEA, RMND5A and ARMC8 each have roles in maintaining complex stability. Importantly, RMND5A and MAEA are completely co-dependent on each other. We found that ubiquitination activity of the complex is dependent on the RING subunits RMND5A and MAEA. Furthermore, both recombinant RMND5A and MAEA also exhibit activity. Additionally, we determined that the complex can pair with ubcH5 family of E2 enzymes and GST-RMND5A can catalyze K48 and K63 ubiquitin chains. Finally, we revealed that CTLH complex regulates ubiquitination and proteasomal degradation of its peripheral subunit muskelin.

Our data suggests that protein expression of several CTLH complex subunits is interdependent, which has previously been observed to some extent for the yeast Gid complex. In the Gid complex, Gid1 (RanBPM) was deemed essential for the stability of the complex as its deletion resulted in decreased levels of Gid8 and Gid2.
Also, Gid2 and Gid9 were found to stabilize each other\textsuperscript{26}. Our analyses of CTLH complex subunits knockdown/knockout cells suggest that this is also true for the CTLH complex. RanBPM knockdown resulted in the decrease of TW A1, RMND5A and MAEA protein levels and RMND5A and MAEA required each other, suggesting that, like in the Gid complex, the two RING domain subunits are stabilized through heterodimerization. TW A1, like RanBPM, is central to CTLH complex formation, as its knockout affected RanBPM, MAEA, RMND5A and, curiously, ARMC8\textsubscript{β}. Finally, muskelin knockout did not significantly affect other CTLH complex members’ protein levels. Previous microarray analyses revealed no changes in CTLH complex members’ RNA expression in RanBPM shRNA cells\textsuperscript{32}, and this was confirmed through qPCR analyses. We did not detect any significant changes in mRNA levels in most other CTLH complex knockout cells, except in 2 cases (RMND5A and ARMC8) where slight changes in mRNA expression were detected but were much more subtle than the effect observed at the protein level. Therefore the changes in protein expression induced by the knockout of individual CTLH sub-units reflect mostly changes in protein stability rather than at the transcriptional level.

We found that both ARMC8\textsubscript{α} and \textsubscript{β} were present in the CTLH complex. These 2 isoforms originate from alternative splicing of the same gene product and have previously been identified as being part of the CTLH complex\textsuperscript{13}. However, it raises the question as to whether both isoforms are present together in the complex or that sub-complexes contain one or the other isoform. Interestingly, the loss of TW A1 had different effects on the two ARMC8 isoforms, with ARMC8\textsubscript{β} being strongly decreased and ARMC8\textsubscript{α} slightly increased, albeit not significantly, inferring that the alternate splicing event may be regulated by the CTLH complex. Reversely, ARMC8 knockout significantly reduced TW A1, MAEA and RMND5A levels, suggesting that ARMC8 may stabilize the association of the core complex members.

Immunofluorescence analyses showed that the CTLH complex subunits are localized to different extents in the cytoplasm and nucleus. The subcellular localization observed with ectopically expressed proteins appear to match that of several endogenously expressed CTLH complex members reported in a previous study\textsuperscript{13}. Adding to that, we found that GID4 is nearly exclusively nuclear, whereas WDR26 is mostly cytoplasmic. This suggests the possibility that several distinct CTLH complex variants exist in the cell. However, the fact that the knockout of MAEA, which is mostly nuclear, affects the levels of muskelin, which is mostly cytoplasmic, implies that these two seemingly differentially localized members are connected. Therefore, the dynamics of the nucleocytoplasmic localization of CTLH complex(es) will need further investigation. Also, our analysis involved ectopically expressed proteins, and while our results show that transfected CTLH complex members can interact with the endogenous CTLH complex (see Fig. 1), it is possible that a significant fraction of the transfected proteins did not associate with the complex and that their observed localization was dictated by their own localization properties rather than by those of the complex as a whole.

Our analyses of the CTLH complex E3 activity through \textit{in vitro} ubiquitination assays using RanBPM immunocomplexes showed that, as expected, RMND5A is essential for activity. MAEA is also likely essential since its KO reduces RMND5A protein levels to background, therefore preventing CTLH complex activity. Also, based
on the yeast topology, MAEA links TWA1 to RMND5A and potentially ARMC8 and therefore is essential for complex formation.

We found that both bacterially-expressed recombinant RMND5A and MAEA have E3 ligase activity. This was previously reported for the *Xenopus laevis* and yeast homologues of RMND5A, However, this is the first time that MAEA is shown to have intrinsic activity. The activity of both RMND5A and MAEA was low, and the reason for this may be that both contain RING domains that diverge considerably from the RING consensus. Analysis of the consensus sequence for RMND5A homologues suggests its RING domain resembles that of TRIM32, but contains serines instead of cysteines in its second active site. TRIM32 exists as a tetramer formed by two separate dimerization events that occur through the RING domains and the coiled-coil region. TRIM32 RING dimerization is essential for catalytic activity. This suggests that this may also be true for the RMND5A-MAEA dimer. Previous analyses with the yeast complex found that the interaction of Gd2 and Gd9 still occurs when the Gd2 CTLH and LisH domains are deleted, suggesting that the interaction may be mediated by the RING domains. In our *in vitro* assays, we expressed RMND5A as a fusion protein with GST. Since GST dimerizes, that could be fulfilling the pre-requisite for dimerization. Alternatively, the LisH and CTLH domains could mediate dimerization and/or the RING domain may have similar dimerization capabilities as TRIM32. The MAEA RING domain is longer than conventional RING domains, is not predicted to coordinate zinc and has no obvious similarities to other eukaryotic RING motifs. As it was expressed as a SUMO-fusion protein, dimerization, if required for activity, could only have been mediated by the RING and/or the LisH/CTLH domains.

Another study recently described the activity of the CTLH complex through biochemical reconstitution with purified components. While some of our conclusions are in agreement with their findings, notably with respect to the requirements for MAEA and the other core complex subunits RanBPM, TWA1 and RMND5A for E3 ligase activity, some of our results differ, in particular regarding the identification of the E2 requirement for complex activity. While we detected robust activity with UBE2D1, UBE2D2 and UBE2D3 variants, we did not observe any activity with UBE2H, or CDC34. In agreement with our data, Lampert et al. did not report any activity with CDC34, however, they found that UBE2H was the most efficient E2 and they observed little activity with...
Figure 7. Muskelin is a target of the CTLH complex. (a) Deregulation of muskelin in RMND5A KO cells can be rescued by restoration of RMND5A expression. HeLa whole cell extracts prepared from control, RMND5A KO, or RMND5A KO cells transfected with HA-RMND5A for 24 hours were analyzed by Western blot with the antibodies indicated. Below, quantification of muskelin levels is shown to the right for untransfected (−) or HA-RMND5A transfected RMND5A KO HeLa cell, normalized to vinculin levels and relative to control cells set to 1. N = 3, error bar indicates SD. **P < 0.01. (b) Muskelin upregulation is proteasome-dependent. Whole cell extracts were prepared from Control or RMND5A KO HeLa cells treated with DMSO or 10 μM MG132 for 16 hours and analyzed by Western blot. Below, quantifications of muskelin in MG132-treated control or RMND5A KO HeLa cells, normalized to actin levels and relative to their DMSO control set to 1. N = 4, error bar indicates SD. **P < 0.01. (c) Degradation kinetics of muskelin. Control or RMND5A KO HeLa cells were treated with 100 μM cycloheximide (CHX) and whole cell extracts were prepared at the times indicated. Samples were run on a 10% SDS-PAGE gel and analyzed by Western blot with the indicated antibodies. Muskelin quantifications are shown below relative to vinculin levels and normalized to untreated samples which were set to 1. N = 3, error bars indicate SD. *P < 0.05. The error bar for the KO samples at 24 h is not visible because it is smaller than symbol size. (d) Ubiquitination of transfected muskelin is regulated by RMND5A. Control or RMND5A KO HEK293 were co-transfected with FLAG-muskelin or HA-ubiquitin (HA-Ub) for 24 hours, followed by 10 μM MG132 treatment for 8 hours. FLAG-muskelin was pulled down in denaturing conditions. Note that transfected muskelin migrates higher than endogenous muskelin due to the added tags that amount to about 7 kDa. (e) Ubiquitination of endogenous muskelin is regulated by RMND5A. Control or RMND5A KO HEK293 were transfected with HA-Ub for 24 hours, followed by 10 μM MG132 treatment for 8 hours. HA-Ub was pulled down in denaturing conditions.
UBE2D3. While UBE2H was identified as the human homologue of Gid328, it lacks the C-terminal extension of acidic residues found in Gid3. This acidic tail is reminiscent of CDC34 in which the tail both binds the E3 ligase and promotes ubiquitin transfer24. Most of their assays involved the in vitro reconstituted CTLH complex with subunits purified from insect cells, whereas our assays involved bacterially-expressed RMND5A and the endogenous CTLH complex immunoprecipitated from HEK293 cells. Another difference is that we assayed complex activity from endogenous RanBPM immunoprecipitates, whereas they assayed the E3 activity from the complex immunoprecipitated through transfected tagged-RMND5A. The use of different experimental models (recombinant versus native complex) or the differences in complex isolation procedure (potentially yielding different complex conformations) as well as the relative activities of E2 enzymes could potentially account for these differences. However, our in vitro assays using recombinant RMND5A are consistent with previous in vitro ubiquitination assays which showed that yeast Gid2 (homolog of RMND5A) was able to function with UBE2D227.

Our finding that muskelin protein levels and ubiquitination are regulated by the CTLH complex provides insight into a possible function and/or regulatory module of the complex. It also raises the question as to whether muskelin has a role in CTLH complex function or if it is just one of its targets. If the former, its appearance later in evolution suggests that it may provide a function to the complex distinct from the yeast Gid complex. As shown in this study and others, muskelin localizes mostly to the cytosol, which is dependent on its LisH domain-mediated dimerization13,20,36–38. Interestingly, its overexpression has previously been shown to promote relocalization of other CTLH nuclear complex members to the cytoplasm38. Therefore, we speculate that the function of muskelin in the CTLH complex may be to direct the complex to specific cytoplasmic targets. Ubiquitination and subsequent degradation of muskelin by the complex could therefore serve as a feedback mechanism under certain conditions. Self-ubiquitination is a common feature of most E3 ligases and in many cases is used as a mechanism of autoregulation39,40.

Muskelin promotes cellular prion protein (PrPc) turnover via the lysosome in neurons and muskelin knock-out accelerates Prion disease induced by prion infection in mice19. Interestingly, a fragment of RanBPM is found overexpressed in Alzheimer’s Disease (AD) patients and its overexpression promotes Amyloid beta (Aβ) generation and hallmarks of AD41–45. As PrPc propagates the neurotoxic signaling effects of Aβ36–44, this could implicate a mechanism whereby the effects observed by RanBPM overexpression in AD are, at least partially, a result of increased ubiquitination and proteasomal degradation of muskelin, leading to a defect in PrPc lysosomal degradation. It will be of interest to assess adult mouse models of other CTLH complex members, especially in the context of neurodegenerative diseases, to determine if there is an interplay between the CTLH complex and muskelin ubiquitination that contributes to disease pathogenesis.

In summary, we have extended the characterization of the mammalian CTLH complex, a unique E3 ligase complex containing a RING heterodimer. We confirmed its function as an E3 ubiquitin ligase and determined the requirements for its stability and activity. We have also revealed it regulates ubiquitination of its subunit muskelin, adding to its list of possible targets and identifying a potential autoregulatory mechanism that awaits further investigation. A comprehensive study of the substrates of the CTLH complex will be informative to understand the biological function of this multi-subunit E3 ubiquitin ligase.

**Methods**

**Cell culture, transfections and treatments.** Wild-type HeLa and HEK293 cells, and control shRNA and RanBPM shRNA stable HEK293 cells have been described previously49,50. All cells were cultured in high glucose Dulbecco’s modified Eagle’s medium (Wisent Bioproducts, St. Bruno, Quebec, Canada) supplemented with 10% fetal bovine serum (Wisent Bioproducts) at 37 °C in 5% CO2. Cells were treated with 10 μM MG132 (EMD-CalBiochem, San Diego, CA) for the indicated time points. For cycloheximide (CHX) treatment, cells were treated with 100 μg/ml cycloheximide (BioShop, Burlington, ON, Canada) and collected at the indicated time points.

Plasmid transfections were carried out with jetPRIME (Polypus Transfection, Illkirch, France) according to the manufacturer’s protocol. siRNA transfections were carried out as described previously51 for siMuskelin and siRMND5A and siTWA1 (Silencer, AM16708A, 25822, Ambion, Life Technologies, Burlington, ON, Canada) transfections were performed using the same conditions.

**Generation of CRISPR Knockout cells.** Single guide RNA (sgRNA) sequences were designed using the Benchling CRISPR tool (https://benchling.com). Top and bottom oligos with overhanging ends containing sgRNA directed against RMND5A (5′-CACCGTGAGACATTTTCCTGACA, 5′-AAACTGTCGAAAGAAGTGCTCCAC) MAEA (5′-CACCGCGGAAGGCTTAGGGGCCGCGG, 5′-AAACCCGGCGGCCCCTAAGCCTTCGC), or muskelin (5′-CACCGCTGTGTTGTTGATGTCAGA, 5′-AAACCTACTGCAATTCGACCAAAC), RanBPM (5′-CACCGCGAAAGGCTTTAGGGCCCGCG, 5′-AAACCCGGCGGCCCCTAAGCCTTCGC), or muskelin (5′-CACCGCTGTGTTGTTGATGTCAGA, 5′-AAACCTACTGCAATTCGACCAAAC) were cloned into pSpCas9(BB)-2A-Puro V2.0 (PX459; Dr. Joe Torchia, Western University, London, ON, Canada), pSpCas9(2B)-2A-Puro V2.0 (PX459; Dr. Lina Dagnino, Western University, London, ON, Canada), and pCMV-HA-muskelin52 (mouse cDNA; Dr. Kai Jiao, University of Alabama at Birmingham, Birmingham, AL, USA). pCMV-HA-RanBPM has been described...
previously49. Primers for RMND5A (5'TGACATTCTAGATGGTGAGCTGCTGAGGAG, 5'TGACATTGATGGTCCAGGAAATATCTGTTGGAC, MAAE (5'TGACATTCTAGATGGTGAGCTGCTGAGGAG, 5’TGACATTCTAGATGGTGAGCTGCTGAGGAG), TW1 (5’TGACATTCTAGATGGTGAGCTGCTGAGGAG), and TW2 (5’TGACATTCTAGATGGTGAGCTGCTGAGGAG), were used to generate inserts amplified from a Jurkat T cell cDNA library (Clontech, see reference49). The inserts were digested with XbaI and BamHI enzymes and cloned into pCGN-HA plasmid (created by removal of Oct-1 from pCGN-Oct-1, see reference55). ARMC8 insert was generated by PCR amplification (5’TATTTAGGTACC′ 5′TACCAG) with Age1 and XhoI sites and subcloned into pCDNA-SBP-FLAG (created by removal of RanBPM from pCMV-HA-RanBPM). Muskelin cDNA (derived from pCMV-HA-muskelin (mouse)) was PCR amplified (5’TATCTCTCCTTCCTGGGAGAGTCTTGTCG, 5’TATCTCTGAGTCCAGTGTGACGAGGAG), and cloned into pCGN-HA plasmid (created by removal of Oct-1 from pCGN-Oct-1, see reference55). ARMC8ΔCt method and reported as fold increase or decrease in mRNA levels in knockout cell line samples relative to control cells.

**RNA extraction, reverse transcription and quantitative PCR.** RNA extraction was performed using RNeasy Mini Kit (QIAGEN, Toronto, Canada) in accordance with the manufacturer’s directions. 2μg of total RNA was reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, California, United States). Quantitative PCR was completed on Bio-Rad CFX Connect Real-Time System (Bio-Rad) using pre-designed TaqMan probes (4448892, Applied Biosystems) for the following genes: RANBP9 (Hs00170646_m1), GID8 (Hs00215479_m1), RMND5A (Hs00405598_m1), MKLN1 (Hs00992683_m1), MAAE (Hs01028524_m1), and ARMC8 (Hs01046446_m1). Experiments were performed with technical triplicates using GAPDH (4453320, Hs02786624_g1, Applied Biosystems) as a normalization control. Changes in gene expression were determined by the 2ΔCt method and reported as fold increase or decrease in mRNA levels in knockout cell line samples relative to control cells.

**Western blot.** Whole cell extracts were prepared as described49 and resolved using 8% or 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Gels were transferred to polyvinylidene fluoride membranes, blocked in 5% milk and hybridized with the following antibodies: ARMC8 (E-1, sc-365307; Santa Cruz Biotechnology, Santa Cruz, CA, USA); FLAG (M2, F1804, Sigma-Aldrich, St. Louis, MO, USA); HA (HA-7, H9658, Sigma-Aldrich); Muskelin (C-12, sc-398956, Santa Cruz Biotechnology); RANBP9 (5M, 71-001, Bioacademia, Japan); RMND5A (NBP1-92337, Novus Biologicals, Littleton, CO, USA); TVA1 (NBP1-32596, Novus Biologicals); Vinculin (E1E9V, Cell Signaling Technology, Danvers, MA, USA); WDR26 (ab58962, Abcam, Cambridge, UK); 3-actin (A5441, Sigma-Aldrich) and Hs (MAB050, R&D Systems). Blots were developed using Clarity Western ECL Substrate (BioRad, Hercules, CA, USA) and imaged using a ChemiDoc MP (BioRad). Analysis and quantifications were done using Image Lab (BioRad).

**Immunofluorescence.** Cells were plated on coverslips and transfected following overnight incubation. Cells were fixed with 3% paraformaldehyde, permeabilized in 0.5% Triton X-100 for 10 min and blocked in 5% FBS diluted in PBS. Coverslips were incubated overnight with primary antibody HA (HA-7, H9658, Sigma-Aldrich) or FLAG (M2, F1804, Sigma-Aldrich), washed in PBS and incubated with anti-mouse Alexa Fluor 488 secondary antibody (Invitrogen, Life Technologies, Burlington, ON, Canada). Cells were mounted with ProLong Gold antifade with DAPI (Invitrogen). Visualization was done using an Olympus BX51 microscope with a 40x objective and images were captured with the Image-Pro Plus software (Media Cybernetics Inc., Bethesda, MD, USA). For quantification analysis, images were blinded by a third party.

**Immunoprecipitations.** For co-immunoprecipitation experiments, extracts were adjusted to 0.25% NP-40, pre-cleared and rotated overnight at 4 °C with antibodies to RANBP9 (F-1, sc-271727, Santa Cruz Biotechnology), HA (HA-7, H9658, Sigma-Aldrich), or FLAG (M2, F1804, Sigma-Aldrich). Samples were then incubated for 1 hour at 4 °C with Dynabeads protein G (10004D, Invitrogen), washed three times in lysis buffer and resuspended in SDS loading buffer. Mouse IgG (sc-2025, Santa Cruz Biotechnology) was used as negative control for RANBP9 immunoprecipitations. For ubiquitination assays, RANBP9 immunoprecipitations were carried out as above, except extracts were supplemented with extra NP-40 (final 1.0%) and Triton (final 0.2%) and washed three times in lysis buffer without EDTA.

To assess ubiquitination of FLAG-muskelin, control or RMND5A KO HEK293 cells were co-transfected with pCDNA-FLAG-muskelin and pMT123 plasmid expressing HA-ubiquitin52. Twenty-four hours after transfection, cells were MG132 treated for 8 hours. Cells were lysed in denaturing buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton, 1% SDS, 1 mM Na3VO4, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 μg/ml of aprotinin, 10 μg/ml of pepstatin, 1 μg/ml of leupeptin and 25 mM NEM (N-Ethylmaleimide, Bioshop Canada, Burlington, ON, Canada)), passed through a 23 G needle ten times and incubated on ice for 30 minutes. For immunoprecipitation, lysates were diluted 1:10 in buffer A (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton, 1 mL Na3VO4, 10 mM NaF and 25 mM NEM) and incubated with anti-FLAG (M2; F1804; Sigma-Aldrich) for 2 hours at 4 °C,
followed by incubation with Dynabeads Protein G for 1 hour. Beads were then washed five times in buffer A and resuspended and boiled in SDS loading dye. Eluates were split in half when loading on SDS-PAGE so that HA and FLAG immunoblotting could be analyzed separately (to avoid overlapping signal). The same procedure was employed for the HA-ubiquitin immunoprecipitation, except that cells were transfected with only HA-ubiquitin plasmid and anti-HA (HA-7, H9658, Sigma-Aldrich) was used for the pulldown.

**In vitro ubiquitination assays.** BL21 E. coli expressing GST, GST-RMND5A, His-SUMO-SLP2 and His-SUMO-MAEA were grown at 37 °C with 250 μM ZnCl₂ to 0.7–0.8 OD600 and induced with 0.5 mM Isopropyl-1-thiogalactopyranoside, then grown at 16 °C overnight. Cells were lysed in 50 mM Tris–HCl, pH 7.5, 250 mM NaCl, 5 mM dithiothreitol (DTT), 2 mM PMSE, 20 μg/mL Leupeptin, 1.0 μg/mL aprotinin and 1% Triton-X 100 and passed through a French press twice. 4.5 μL of bacterial extract was used in a 20 μL ubiquitination reaction with 5 μM UBE2D2 (E2-622, BostonBiochem, Cambridge, MA), 0.1 μM His-tagged E156, 25 μM His-ubiquitin, 10 mM Mg-ATP (B-20, R&D Systems), 50 mM Tris–HCl, pH 7.5, 50 mM NaCl, 10 mM MgCl₂, 0.1 mM DTT and 25 μM ZnCl₂. The UbcH (E2) Enzyme Kit (K-980B, BostonBiochem) and CDC34 (see reference⁷⁷) was used to screen E2 enzymes. Reactions were incubated in a thermomixer with periodic shaking at 37 °C for 2 hours. The entire reactions were run on an 8% SDS-PAGE and analyzed by Western blot. For ubiquitination assays with RanBPM immunocomplexes, beads were resuspended in 0.1 μM His-tagged E1, 5 μM UbcH5b, 22.5 μM His-ubiquitin, 2.5 μM Ub⁻⁶⁸⁰ (see reference⁸⁰), 10 mM Mg-ATP and 50 mM HEPES. Reactions were incubated in a thermomixer with periodic shaking at 37 °C for 30 minutes. Gels were scanned by the Odyssey Imaging system (LiCor, Lincoln, NE, USA) and fluorescence intensity was measured at 800 nm.

**Chain linkage analysis by Mass Spectrometry (MS).** Sample preparation of GST-RMND5A ubiquitination reactions were performed as described previously⁷⁹,⁸⁰. Briefly, reactions were reduced with 10 mM DTT, alkylated with 100 mM Iodoacetic acid, followed by methanol precipitation. The protein pellet was resuspended in 0.5% PPS Silent Surfactant (Expedeon Ltd, Cambridge, UK) and digested for 16 hours with 0.5 mg of Lysyl Endopeptidase (LysC; 125-05061, Wako Pure Chemical Ind., Ltd., Japan) and 0.75 mg of LysC/Trypsin (V5071, Promega, Madison, WI, USA), followed by 4 hours with 0.5 mg Trypsin (V5111, Promega). Quenched digested reactions were then desalted with C18 Stage Tips and eluted peptides were lyophilized, followed by resuspension in 0.1% Formic acid. Samples (1 μg as measured by BCA) were analyzed by using an M-class nanoAquity UHPLC system (Waters, Milford, MA, USA) connected to a Q Exactive mass spectrometer (Thermo Scientific, Waltham, MA, USA). Raw MS files were searched in MaxQuant (version 1.5.8.3) using the Human Uniprot database. MS1 and MS2 parameters were used. For the analysis of linkages, the MaxQuant settings were set: Maximum missed cleavages 2; Max. number of variable modifications 3; Prec. mass tolerance ± 10 ppm; Frag. mass tolerance ± 0.05 Da; Engine MS/MS: PEAKS (v10.0). The detection of mono- and di-linked chains was reported in a linked MS/MS heat map. 

**Statistical analysis.** Statistical analyses were performed using GraphPad PRISM (GraphPad Software Inc., La Jolla, CA, USA). Differences between two groups were compared using unpaired two-tailed t test. Results were considered significant when P < 0.05.

**References**

1. Rape, M. Ubiquitylation at the crossroads of development and disease. *Nat. Rev. Mol. Cell Biol.* 19, 59–70 (2017).
2. Komander, D. & Rape, M. The Ubiquitin Code. *Annu. Rev. Biochem.* 81, 203–229 (2012).
3. Pickart, C. M. Mechanisms Underlying Ubiquitination. *Annu. Rev. Biochem.* 70, 503–533 (2001).
4. Budhidarmo, R., Nakatani, Y. & Day, C. L. RINGs hold the key to ubiquitin transfer. *Annu. Rev. Biochem.* 78, 751–784 (2009).
5. Sarikas, A., Hartmann, T. & Pan, Z.-Q. The cullin protein family. *Annu. Rev. Biochem.* 81, 583–618 (2012).
6. Pickart, C. M. Mechanisms Underlying Ubiquitination. *Annu. Rev. Biochem.* 70, 503–533 (2001).
7. Santt, O. et al. Proteins of newly isolated mutants and the amino-terminal proline are essential for ubiquitin-proteasome-catalyzed catabolite degradation of fructose-1,6-bisphosphate of Saccharomyces cerevisiae. *Cell Biol. Chem.* 273, 25000–5 (1998).
8. Francis, O., Han, F. & Adams, J. C. Molecular Phylogeny of a RING E3 Ubiquitin Ligase, Conserved in Eukaryotic Cells and Dominated by Homologous Components, the Muskelin/RanBPM/CTHL Complex. *Plos One* 8, e75317 (2013).
9. Braun, B. et al. Gid9, a second RING finger protein contributes to the ubiquitin ligase activity of the Gid complex required for catabolite degradation. *FEBS Lett.* 585, 3856–3861 (2011).
10. Pfirrmann, T. et al. RMND5 from Xenopus laevis is an E3 Ubiquitin-Ligase and Functions in Early Embryonic Forebrain Development. *Plos One* 10, e0123042 (2015).
11. Kobyashi, N. et al. RanBPM, Muskelin, p48EMLP, p44CTHL, and the armadillo-repeat proteins ARMC8a and ARMC8b are components of the CTHL complex. *Gene* 396, 236–247 (2007).
12. Umeda, M., Nishihata, H. & Nishimoto, T. A novel nuclear protein, Twa1, and Muskelin comprise a complex with RanBPM. *Gene* 303, 47–54 (2003).
13. Saleni, I., Maitland, M. E. R., McTavish, C. J. & Schild-Poulter, C. Cell signalling pathway regulation by RanBPM: Molecular insights and disease implications. *Open. Biol. 7*, 170081 (2017).
14. Palmieri, D., Tessari, A. & Coppola, V. Scorpions in the DNA Damage Response. *Int. J. Mol. Sci.* 19, 1794 (2018).
15. Palmieri, D. et al. Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells. *Oncotarget* 7, 18371–83 (2016).
16. Javan, G. T., Salhotra, A., Finley, S. J. & Soni, S. Erythrobласт macrophage protein (Emp): Past, present, and future. *Eur. J. Haematol.* 100, 3–9 (2018).
17. Heider, F. E. et al. Muskelin Coordinates PrPC Lyosomal versus Exosome Targeting and Impacts Prion Disease Progression. *Neuron* 99, 1155–1169.e9 (2018).
18. Adams, J. C., Seed, B. & Lawler, J. Muskelin, a novel intracellular mediator of cell adhesive and cytoskeletal responses to thrombospondin-1. *The EMBO Journal* 17 (1998).
21. Heisler, F. E. et al. Muskelin Regulates Actin Filament- and Microtubule-Based GABAAR Receptor Transport in Neurons. Neuron 70, 66–81 (2011).

22. Leaf-Esteban, L. C., Rothé, B., Fortier, S., Isenschmid, M. & Constand, D. B. Role of Bicaudal C1 in renal glucosehomeostasis and its novel interaction with the CTLH complex. PLoS Genet. 14, e1007487 (2018).

23. Salemi, L. M., Matlaid, M. E. R., Yetef, E. R. & Schild-Poulter, C. Inhibition of HDAC6 activity through interaction with RanBPM and its associated CTLH complex. BMC Cancer 17, 460 (2017).

24. Teyler, V. et al. Elution profile analysis of SDS-induced subcomplexes by quantitative mass spectrometry. Mol. Cell. Proteomics 13, 1382–91 (2014).

25. Anvarian, Z. et al. Axin cancer mutants form nanoaggregates to rewire the Wnt signaling network. Nat. Struct. Mol. Biol. 23, 324–332 (2016).

26. Mensen, R. et al. Exploring the Topology of the Gid Complex, the E3 Ubiquitin Ligase Involved in Catabolite-induced Degradation of Glucagonogenic Enzymes. J. Biol. Chem. 287, 25602–25614 (2012).

27. van Wijk, S. J. L. et al. A comprehensive framework of E2-RING E3 interactions of the human ubiquitin-proteasome system. Mol. Syst. Biol. 5, 295 (2009).

28. Kaiser, P. et al. A human ubiquitin-conjugating enzyme homologous to yeast UBC8. J. Biol. Chem. 269, 8797–802 (1994).

29. Schüle, T., Rose, M., Entian, K.-D., Thumm, M. & Wolf, D. H. Ubc8p functions in catabolite degradation of fructose-1,6-bisphosphatase in yeast. EMBO J. 19, 2161–2167 (2000).

30. Regelmann, J. et al. Catabolite Degradation of Fructose-1,6-bisphosphatase in the Yeast Saccharomyces cerevisiae: A Genome-wide Screen Identifies Eight Novel GID Genes and Indicates the Existence of Two Degradation Pathways. Mol. Biol. Cell 14, 1652–1663 (2003).

31. Kleiger, G., Hao, B., Mohl, D. A. & Deshaies, R. J. The acidic tail of the Cdc34 ubiquitin-conjugating enzyme functions in both binding to and catalysis with ubiquitin ligase SGC4c. J. Biol. Chem. 284, 36012–36023 (2009).

32. Atabakhsh, E., Wang, J. H., Wang, X., Carter, D. E. & Schild-Poulter, C. RanBPM expression regulates transcriptional pathways involved in development and tumorigenesis. Am. J. Cancer Res. 2, 549–65 (2012).

33. Koliopoulos, M. G., Esposito, D., Christodoulou, E., Taylor, I. A. & Rittinger, K. Functional role of TRIM E3 ligase oligomerization and regulation of catalytic activity. EMBO J. 35, 1204–1218 (2016).

34. Streich, F. C., Ronchi, V. P., Connick, J. P. & Haas, A. L. Tripartite motif ligases catalyze polyubiquitin chain formation through a cooperative allosteric mechanism. J. Biol. Chem. 288, 8209–8221 (2013).

35. Lampert, F. et al. The multi-subunit GID/CTLH e3 ubiquitin ligase promotes cell proliferation and targets the transcription factor Hfp1 for degradation. Elife 7, e35528 (2018).

36. Ledere, D. R. et al. A specific interaction between muskelin and the cyclin-dependent kinase 5 activator p39 promotes peripheral localization of muskelin. J. Biol. Chem. 280, 21376–83 (2005).

37. Delto, C. F. et al. The LisH Motif of Muskelin Is Crucial for Oligomerization and Governs Intracellular Localization. Structure 23, 364–373 (2015).

38. Valiavettill, M. et al. Novel role of the muskelin–RanB9 complex as a nucleocytoplasmic mediator of cell morphology regulation. J. Cell Biol. 182, 727–739 (2008).

39. Vittal, V., Stewart, M. D., Bezovic, P. S. & Klevit, R. E. Regulating the regulators: Recent revelations in the control of E3 ubiquitin ligases. Journal of Biological Chemistry 290, 21244–21251 (2015).

40. De Bie, P. & Ciechanover, A. Ubiquitination of E3 ligases: self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms. Cell Death Differ. 18, 1393–1402 (2011).

41. Woo, J. A. et al. RanB9 at the intersection between coflin and Aβ pathologies: rescue of neurodegenerative changes by RanB9 reduction. Cell Death Dis. 6, 1676 (2015).

42. Wang, H., Wang, R., Xu, S. & Lakshmana, M. K. RanB9 Overexpression Accelerates Loss of Pre and Postsynaptic Proteins in the AD/ΔE9 Transgenic Mouse Brain. J. Biol. Chem. 284, 2072–2083 (2012).

43. Lakshmana, M. K. et al. Novel Role of RanB9 on amyloidogenic processing of APP and synaptic protein levels in the mouse brain. FASEB J. 26, 2072–2083 (2012).

44. Lakshmana, M. K. et al. Novel Role of RanB9 in BACE1 Processing of Amyloid Precursor Protein and Amyloid β Peptide Generation. J. Biol. Chem. 284, 11863–11872 (2009).

45. Nygaard, H. B. & Strittmatter, S. M. Cellular Prion Protein Mediates the Toxicity of β-Amyloid Oligomers. Arch. Neurol. 66, 1325–8 (2009).

46. Laurén, J. Cellular Prion Protein as a Therapeutic Target in Alzheimer’s Disease. J. Alzheimer’s Dis. 38, 227–244 (2013).

47. Zhou, J. & Liu, B. Alzheimer’s disease and prion protein. Intractable rare Dis. Res. 2, 35–44 (2013).

48. Atabakhsh, E., Bryce, D. M., Lefebvre, K. J. & Schild-Poulter, C. RanBPM Has Proapoptotic Activities That Regulate Cell Death Pathways in Response to DNA Damage. Mol. Cancer Res. 7, 1962–1972 (2009).

49. Atabakhsh, E. & Schild-Poulter, C. RanBPM Is an Inhibitor of ERRK Signaling. PLoS One 7, e47803 (2012).

50. Sun, Z., Tang, X., Lin, F. & Chen, S. The WD40 repeat protein WDR26 binds GTPγS and promotes GTPγS-dependent signal transduction and leukocyte migration. J. Biol. Chem. 286, 43902–12 (2011).

51. Treier, M., Staszewski, L. M. & Bohmann, D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78, 787–98 (1994).

52. Debebedittis, P., Harmelink, C., Chen, Y., Wang, Q. & Jiao, K. Characterization of the novel interaction between muskelin and TBX20, a critical cardiogenic transcription factor. Biochem. Biophys. Res. Commun. 409, 338–43 (2011).

53. Schild-Poulter, C. et al. The binding of Kυ antigen to homeodomain proteins promotes their phosphorylation by DNA-dependent protein kinase. J. Biol. Chem. 276, 16848–56 (2001).

54. Schild-Poulter, C., Shih, A., Yarmyshovich, N. C. & Haché, R. J. G. Down-regulation of histone H2B by DNA-dependent protein kinase in response to DNA damage through modulation of octamer transcription factor 1. Cancer Res. 63, 7197–203 (2003).

55. Condos, T. E. et al. Synergistic recruitment of UbcH7–Ub and phosphorylated UNI domain triggers parkin activation. EMBO J. e100014 https://doi.org/10.15222/embj.2018100014 (2018).

56. Spratt, D. E. & Shaw, G. S. Association of the Disordered C-terminus of CDC34 with a Catalytically Bound Ubiquitin. J. Mol. Biol. 407, 425–438 (2011).

57. Aguirre, J. D., Dunkeler, K. M., Lam, R., Rusai, M. & Shaw, G. S. Impact of altered phosphorylation on loss of function of juvenile Parkinsonism-associated genetic variants of the E3 ligase parkin. J. Biol. Chem. 293, 6337–6348 (2018).

58. Kulpinan, M., Dieters-Castator, D. Z., Hess, D. A., Postovit, L.-M. & Lajoie, G. A. Comparison of sample preparation techniques for large-scale proteomics. Proteomics 17, 1600337 (2017).

59. Hong, J. H., Ng, D., Srikumar, T. & Raught, B. The use of ubiquitin lysine mutants to characterize E2-E3 linkage specificity: Mass spectrometry offers a cautionary “tail”. Proteomics 15, 2910–2915 (2015).
Acknowledgements
We thank members of Schild-Poulter, Lajoie and Shaw labs for helpful discussions, technical help and advice. This work was supported by operating grant MOP-142414 from the Canadian Institutes for Health Research (CIHR) to C.S.-P and MOP-14606 from CIHR to G.S.S. Mass spectrometry analyses were performed on equipment funded by a grant from the Canada Foundation for Innovation to G.A.L. M.E.R.M. was supported by an Ontario Graduate Scholarship (OGS), a fellowship from the Cancer Research & Technology Transfer (CaRTT) Strategic Training Program and a Postgraduate Doctoral scholarship from the Natural Sciences and Engineering Research Council of Canada (NSERC). C.A.C. was supported by a CaRTT fellowship. G.O. was supported by a CaRTT Summer Studentship and an OGS.

Author Contributions
C. Schild-Poulter and G.S. Shaw designed research; M.E.R. Maitland, G. Onea, C. Chiasson, X. Wang, J. Ma, S. Moor and K.R. Barber performed research; C. Schild-Poulter, G.S. Shaw and M.E.R. Maitland analyzed data; G. A. Lajoie contributed reagents and analytical tools; M.E.R. Maitland and C. Schild-Poulter wrote the paper.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-46279-5.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019